CH25H and metabolic disease: Wan-Su Choi et al.’s research on Nature indicated that OA is a disease associated with metabolic disorders and suggest that targeting the CH25H (cholesterol 25-hydroxylase)-CYP7B1(25-hydroxycholesterol 7α-hydroxylase)-RORα axis of cholesterol metabolism may provide a therapeutic avenue for treating osteoarthritis10.